[Evaluation of some functions of polymorphonuclear granulocytes in lung cancer patients during chemotherapy].
Lung cancer (NSCLC and SCLC) is one of most frequent carcinoma. Lung cancer is at the top of the list of cancers causing mortality in males. Many patients are qualified to chemotherapy which causes neutropenia. The aim of this work was to evaluate the number and function of (phagocytosis, test of NBT reduction and MPO activity) of leukocytes in patients with lung cancer before chemotherapy, during leukopenia and after stimulation with granulocyte colony stimulating factor (G-CSF). Patients with lung cancer have increased number of leukocytes before the treatment. After chemotherapy the number of leukocytes decreases. Treatment with G-CSF increases the number of leukocytes but it doesn't increase their ability to phagocytosis and to NBT reduction.
Panek
Beata
B
Z Kliniki Chorób Płuc i Gruźlicy Akademii Medycznej w Białymstoku.
Chyczewska
Elzbieta
E
Ossolińska
Maria
M
Naumnik
Wojciech
W
Izycki-Herman
Tomasz
T
Korniluk
Małgorzata
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006098:Granulocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D010587:Phagocytosis / Q000187:drug effects
D016179:Granulocyte Colony-Stimulating Factor; D002945:Cisplatin